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Increased life expectancy has led to the presentation of more complicated patients in old age for the replacement
of the aortic valve. The emergence of Transcatheter Aortic Valve Implantation (TAVI) was considered as a significant
breakthrough in the management of symptomatic, moribund patients suffering from aortic valve stenosis who had
been rejected for surgical intervention. A novel technology often has a long journey from the point at which it is
created to its every-day-use. It is now obvious that TAVI practice in multiple institutes around the world has gone
beyond the evidence. Serious concerns have been raised questioning the current TAVI practice. Analysis of future
TAVI use may assist clinicians and healthcare managers to understand and deploy this technology in accordance
with the evidence.
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In the spring of 2002 Alain Cribier deployed the first
transcatheter valve implantation in a moribund patient
who had been rejected for surgery [1]. In January 2004
Edward Lifesciences (Inc. Irvine, CA, USA) began mass
production of catheters over which an expandable valve
can be driven into the aorta up to its anatomical position
at the aortic root [2].
Traditionally a new technology in medicine is evalu-
ated on the basis of its safety, efficacy and effectiveness.
In addition Markov model can be used for economical
evaluations [3]. We did not examine the TAVI technol-
ogy according to the aforementioned criteria and tools
while our main focus was to analyse the TAVI trends by
using the Gartner Hyper curve [4].
The literature was searched via Medline using the
OVID interface and where appropriate the level of
evidence is mentioned according to the Oxford
Centre for Evidence-based Medicine (OCEBM) [5]
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In 1995 the Gartner Company (Inc., Stamford, CT,
USA), an information technology research and develop-
ment corporation introduced a new tool called “Hype”
cycle to analyse the behaviour of any emerging technol-
ogy and assist organisations and investors to predict the
technology trends [3]. As TAVI has been certified and
recognised as a technology [6] (level 5), it is appropriate
to analyse its behaviour since creation using the Hype
cycle phases (Figure 1).Phase 1: technology trigger
TAVI did not reach the stage of product launch until
Edward Lifesciences (Inc., Irvine, CA, USA) produced
SAPIEN® valves; closely followed by the Medtronic
CoreValve® (Medtronic Inc, MN, USA). The product
launch was disseminated by Leon et al. [7] (level 1B),
who first published the results of a randomised con-
trolled trial comparing TAVI vs. medical therapy/valvu-
loplasty vs. Aortic Valve Replacement (AVR). The results
of PARTNER studies [7-10] (level 1B) have been widely
used for of the promotion of TAVI programmes and sig-
nificantly influenced the management of high-risk pa-
tients [11] (level 5). These studies demonstrated that in
selected high risk patients suffering from aortic stenosis
the survival in 1-year was similar in TAVI and AVR. Ittral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 TAVI Gartner-Hype curve.
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alternative to AVR in high risk patients who were not
suitable candidates for surgery.
The guideline published recently by the joint task
force on the management of valvular heart disease of the
European Society of Cardiology (ESC) and the European
Association for Cardio-Thoracic Surgery (EACTS), has
also recommended TAVI for high risk patients who are
not suitable for surgery [12].
Phase 2: peak of inflated expectations
This phase was reached following TAVI interventions
conducted throughout the world; this recently exceeded
40,000 procedures [13]. In fact, TAVI may reach the
peak of the Hype cycle in a relatively short period of
time owing to the enthusiasm of pro-TAVI clinicians
and industry marketing pressures. Germany, as the lar-
gest consumer of this technology in Europe [13], did not
have a reliable registry until the creation of the German
Aortic Valve Registry (GARY) in 2010 [14], implying a
haphazard recruitment of patients for TAVI on a large
scale. In Canada, 6 years prior to United States Food
and Drug Administration (FDA) approval, the TAVI
programme was limited to patients on compassionate
grounds and recruited a number of patients within four
years. Although it has been demonstrated that TAVI is
in consistence with post-operative paravalvular regurgi-
tation and stroke, the TAVI programme continued to re-
cruit larger number of patients by expanding the criteria
and lowering the bar of risk stratification. Concerns have
been expressed that potential TAVI candidates constitute
a widely heterogeneous group of patients [15] (level 4);
this may directly influence a bias-free patient recruit-
ment for TAVI programmes. Retrospective analysis of
outcomes of conventional AVR in high-risk patients who
are also potential candidates of TAVI, demonstrated that
widening of the inclusion criteria for TAVI may be in-
appropriate [16] (level 4).Currently, there are no clear guidelines available to as-
sist the surgeons in determining which patients would
best be treated by TAVI or AVR. In 2012 a group of in-
dependent researchers [6] claimed that more than
40,000 TAVI procedures which have been performed
throughout the world cannot be justified from both a
clinical and cost-effectiveness point of view. The analysis
criticises the clinicians who have manipulated the indica-
tions to beyond the evidence in TAVI practice.
Neil Moat, the principle investigator of the first major
UK TAVI registry [17], says “We have enough experi-
ence with TAVI now that we have to accept that the de-
vices are different and they do have different advantages
and disadvantages, and I think it’s excellent that we are
starting to discuss the type of patients that would benefit
from one device or another” [13]. This statement also
confirms that the TAVI technology is currently at its
peak of inflated expectations moving towards the
“Trough of disillusionment” phase.
Phase 3: trough of disillusionment
This phase has not yet arrived for TAVI. In this se-
quence the use of the technology visibly diminishes indi-
cating that it has just become unfashionable. In this
stage the rate of publication of TAVI-related articles
topics reduces significantly.
Phase 4: slope of enlightenment
The Scottish Government report on TAVI [18] (level 5)
confirms that: “There is no consensus on what consti-
tutes high surgical risk, no reliable method to identify
elderly patients are most likely to benefit from AVR and
no standard criteria by which to select patients for
TAVI.” Although the report confirmed that TAVI must
be only used in patients who are considered as inoper-
able it concluded: “There is a lack of standardisation of
the definitions of “inoperable” and “high risk” as they are
primarily based on clinical judgement.” The report also
revealed that the minimum cost of the procedure is
£21,059 whereas for AVR is much less. The report con-
cluded that TAVI for inoperable patients is more expen-
sive yet, at the same time, more effective than medical
therapy. However there is a paucity of evidence with
regards to economic burden of TAVI.
In 2011 Hartzell Schaff in the editorial section of the
New England Journal of Medicine [19] (level 5) raised
his concerns regarding the large risk of stroke in TAVI
patients which can be up to 8.3% in 1 year [8]. He also
noted that TAVI does not remove the disease therefore
the diseased valve may create an irregular zone which
makes the patient vulnerable to thromboembolic events.
Alain Cribier has also expressed concerns regarding the
extensive deployment of this technology without a suffi-
cient follow-up on the durability. He says: “I have to
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are good surgical candidates with TAVI. The issue is
that, the long-term durability of the TAVI valve is un-
known, but the surgical technique lasts for 20 years” [2].
In this phase the true understating of TAVI technology
needs to be achieved. This includes the TAVI capability
with transparent advantages and disadvantages.
Phase 5: plateau of productivity
In the guideline published by the National Institute for
Health and Clinical Excellence [20] it was emphasised
that there is sufficient evidence of serious complications
of TAVI. Although the NICE guideline clearly states that
TAVI is the treatment of choice for patients not suitable
for surgery, it does not clarify the definite contraindica-
tions to conventional surgery. It is sometimes the case
that a surgeon’s decision to deny a patient conventional
surgery, has been altered by another surgeon who subse-
quently operated upon the same patient with satisfactory
outcomes. It has been previously demonstrated that
AVR rejection constitutes a high degree of subjectivity
[21] (level 4).
At this stage a consensus on the actual use of TAVI in
daily practice needs to be achieved in order to minimise
the bias and subjectivity of decision making process.
Both latter phases would be achieved when a standar-
dised protocol is available by which the high risk pa-
tients can be precisely rejected for surgery.
Conclusion
When Percutaneous Coronary Intervention (PCI) took
over the Coronary Artery Bypass Graft (CABG) practice
in a large number of patients it was not predictable that
coronary stenting will soon go beyond the evidence and
even reach to malpractice [22]. The warning given by
Van Brabandt et al. [6] is important to avoid the mis-
takes of PCI practice and adhere to the evidence in pro-
moting the TAVI programme. Hype cycle can be used as
a road map to facilitate the progress of TAVI as an ad-
junct to AVR to treat moribund inoperable patients and
aid healthcare planning.
Multidisciplinary approach is the foundation of TAVI
practice and the “heart team” comprising the cardiolo-
gists, surgeons and anaesthetists must be the core of the
practice for all referred patients.
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